Saroglitazar: Targeting Non-Alcoholic Steatohepatitis, a Potential US$35-40 Billion Market.
Nonalcoholic fatty liver disease (NAFLD), a disorder characterized by fatty changes (and fibrosis in later stages) is expected to affect about 20...
642 Views
Laurus Labs IPO Overview
India-based Laurus Labs has filed for a listing on the BSE and NSE, and reportedly plans to raise up to Rs300 crore for debt repayment and general...
340 Views
Cadila Healthcare: Potential More than 30% Upside.
Cadila Healthcare Ltd (CDH IN) is the 4th largest pharmaceutical company in India and 9th largest generic drug company in the U.S. At FY 2018 P/E...
298 Views
Thoughts on GILD – a Deep-Valued Growth Stock!
I see Gilead Sciences, Inc. as deep valued growth stock with very large margin of safety over the medium long term. Any sell-off along with the...
453 Views